

# Balaxi Pharmaceuticals Limited

To

2<sup>nd</sup> August, 2022

Listing Department,  
National Stock Exchange of India Limited  
Exchange Plaza, Plot No C/1, G Block, BKC,  
Bandra (E), Mumbai-400051

**Stock Code: BALAXI**

**Sub: Investor Presentation Q1 FY 2022-23**

Dear Sir/Madam,

We hereby attach the **Investor Presentation** issued by the Company. This is for your information and dissemination on your website.

The said information is also being made available on the website of the Company at [www.balaxipharma.in](http://www.balaxipharma.in)

Yours Faithfully,

For Balaxi Pharmaceuticals Limited



Chinta Shalini  
Company Secretary



**Registered Office:**

2<sup>nd</sup> Floor, Maps Towers, Plot No.409, Road No. 81, Jubilee Hills, Phase-III, Hyderabad, Telangana, India - 500096.

CIN: L25191TG1942PLC12'598

Phone: +91 40 23555300 | Email: [info@balaxi.in](mailto:info@balaxi.in) | Website: [www.balaxipharma.in](http://www.balaxipharma.in)

# Balaxi

Pharmaceuticals Limited



*Branded IPR-driven Pharma Player in Frontier Markets*

*Q1FY23 Financial Results*

# Disclaimer

*Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Balaxi Pharmaceuticals Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*

# Contents





04 Corporate Snapshot

15 Financial Highlights

21 Strategic Roadmap




# Bridging the Supply Gap in Frontier Markets



# Successful Produce, Stock, Sell Business Model

<b>Markets</b>	Established operations: Guatemala (Latin America), Dominican Republic (Caribbean) and Angola (Africa) New operations: Honduras (Latin America)	Expansion initiated: El Salvador, Nicaragua, Ecuador, Chile (Latin America) Central African Republic, Zambia (Africa)
<b>Products</b>	Vast range of essential OTC medicines – with healthy mix of generics and branded generics	649 product registrations in five countries 625 registrations submitted or in the pipeline
<b>Supply Chain</b>	Outsourced production from WHO GMP certified plants in India, China and Portugal	Establishing EU GMP compliant facilities in Hyderabad
<b>Distribution</b>	Deep presence through 37 warehouses and on-ground fleet support	Successful process being replicated in other frontier markets; expansion plans in other global markets over near to medium term
<b>Transformation</b>	New initiatives strengthening functionality in supply chain, regulatory affairs and customer service	Centralized digital procurement, regulatory management and customized CRM tools

# Key Success Factors



## Market Selection Methodology

- Focus on countries with high-potential economic growth framework
- Identify non-English speaking countries with similar characteristics
- Low competitive intensity and potential to establish top-2 position
- On-ground feedback mechanism allows deep understanding of demand dynamics
- As population crosses prosperity thresholds, healthcare spends expand exponentially

## Human Capital Management

- Established unique ecosystem of 100+ Indian expatriates in operating geographies
- Financial security ecosystem for key personnel, creating a highly motivated leadership team
- Local language training and support from local staff improves on-ground effectiveness
- Home grown management systems have already proven successful in several countries
- Homogeneous target markets allow cross-movement of people and resources

## Regulatory Affairs Systems

- Appreciation and full compliance of local regulatory framework
- Comprehensive, in-house capabilities backed by cross-functional coordination with business/tech teams
- Digitization of regulatory operations with end-to-end management and data security
- Typical 12-18 month regulatory process is monitored at every stage – supports corporate planning and creates strong local IP


# Transition from “Asset Light” to “Asset Right”



*As a part of its corporate evolution, Balaxi is moving its business model from ‘Asset Light’ to ‘Asset Right’. The company is setting up an EU GMP compliant pharmaceutical manufacturing unit for which it has acquired land in a Pharma SEZ located at Jadcherla, Hyderabad.*



# Investment in Manufacturing Facilities



## Setting up EU GMP compliant pharma manufacturing unit

*General Oral Solid Dosage (OSD) and Liquid Injection formulations*

*Targeting demand for high quality products in Latin American markets*

*Allows full backward integration of supply chain*

*Production from Pharma SEZ unit near Hyderabad by March 2024*

*Historically, Balaxi has successfully executed on its “produce, stock and sell” model. The company has built a large and diversified portfolio of products and a leading position by bridging the supply gap in several countries, first in low-regulation markets in Africa and more recently in semi-regulated markets in Latin America. This outreach has been backed by outsourced, WHO GMP compliant, diversified supply chains developed by the company. As a part of its corporate evolution, Balaxi is now setting up an EU GMP compliant pharmaceutical manufacturing unit to cater to the demand for high quality products in existing as well as targeted markets.*

## Favorable ROI on Capital Expenditure

*Immediate demand for new production from established markets*

*Higher efficacy, greater acceptance, enhanced profit margins*


*Strong control over manufacturing ecosystem*

*Improved regulatory processes, reduced time-to-market for new launches*


*Opens up several new market opportunities globally*

*Production from the unit, located at a Pharma SEZ near Hyderabad, will commence by March 2024, focusing on General Oral Solid Dosage (OSD) and Liquid Injection formulations markets in Latin America. This will drive backward integration of the supply chain to these countries, currently outsourced through contract manufacturing relationships. This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit margins. From the operations standpoint, Balaxi will establish a manufacturing ecosystem that affords better control, improves regulatory processes and reduces time to market for new product launches. Over the medium term, Balaxi sees several new market opportunities opening up for its product lines.*


# Global Footprint



# Key Milestones



# Corporate Structure



# Experienced Board of Directors



## Ashish Maheshwari

Chairman & Managing Director  
Founder of the company, first generation entrepreneur, qualified Chartered Accountant



## Minoshi Maheshwari

Non-Executive Director  
Co-founder, 20 years of rich experience with Balaxi



## Kunal Bhakta

Independent Director  
Chartered Accountant with 15 years' experience, manages First Water Capital, a SEBI registered listed markets AIF



## Gandhi Gamji

Independent Director  
MBA and Bachelors in Engineering, heads successful niche specialty paints and ink chemicals business in Africa/GCC



## M.S. Rao

Independent Director  
MBA from Asian Inst of Mgt, Manila; PGD from IIM-A, Cornell, Kansas State University  
Ex-CEO, Cereals System Initiative for S Asia promoted by Bill & Melinda Gates Foundation



## Purnima Kamble

Independent Director  
LLB from Univ of Lucknow, Heads Hyderabad practice of Fox Mandal, Solicitors & Advocates; 23 years' experience in corporate and commercial law

# Strong Leadership Team



## **Ashish Maheshwari**

### **Chairman & Managing Director**

Founder of the company, first generation entrepreneur, qualified Chartered Accountant  
Commenced business by supplying white labelled pharmaceuticals formulations to various importers  
Established Balaxi Group as a conglomerate spanning four continents  
Recognizes and appreciates knowledge, discipline, transparency and accountability



## **Amol Mantri**

### **CFO**

Qualified Chartered Accountant and Certified Public Accountant from USA  
Associated with Balaxi Group since 2012  
Inherent talent in designing and implementing systemic processes, checks and balances in all operations of the company  
Clear understanding of the company's businesses spread across four continents and seven countries



## **Pranav Maheshwari**

### **Head – Latin America**

BBA and Economics Graduate from Emory University, Atlanta  
Keen observer, quick learner, leads from the front  
Oversees the company's vision for Latin America



## **Paridhi Maheshwari**

### **Head – Alternate Channels**

Currently pursuing MBA at London Business School  
BBA Graduate from University of Southern California, Los Angeles  
Stickler for well-defined systems and processes  
Initiated and leads the consumer products business

# Regional Teams



**Ram Chawla**  
Country Head – Angola



**Jignesh Dinesh Kumar Shah**  
Financial Controller – Angola



**Laksh Shewakramani**  
Compliance Head – Angola



**Pankaj Singh**  
Head of Operations – Guatemala




**Manish Jumnani**  
Sales Head – Guatemala



**Karan Kapoor**  
Head of Operations –  
Dominican Republic



**Bharat Jawarani**  
Sales Head –  
Dominican Republic



# FINANCIAL HIGHLIGHTS







# Management's Comments

*“Our revenue growth of 42% during Q1 is driven by strong volume contribution from Latin American markets. We have also derived translation benefits from a strong currency in Angola. Gross margin expanded significantly, once again based on the strength of the growing Latin American business. In these markets, product margins are intrinsically higher and especially for value-added, branded portfolios, a clear area of focus for Balaxi.*

*The company's operating cost structure – both people and organizational costs – has increased substantially with the entry into several new markets. This includes establishment and product registration expenses in countries that are not contributing to sales at present. Going forward, as business scales up, we expect a positive contribution to revenue growth as well as geographical diversification.*

*As indicated previously, we are making good progress on the planned EU GMP-compliant manufacturing facility near Hyderabad. Production is expected to commence by March 2024, focusing on General Oral Solid Dosage (OSD) and Liquid Injection formulations in Latin American markets where we are rapidly gaining visibility. The estimated project investment of Rs. 85 crore will be financed partly from internal accruals and a judicious mix of additional capital. With the seamless transition from outsourcing to manufacturing in existing geographies, we see a strong payback apart from several strategic benefits for the business from this investment.”*



**Ashish Maheshwari**  
Chairman & Managing Director

 **42%**  
Revenues

 **106%**  
Gross Profit

 **21%**  
EBITDA

 **32%**  
Profit After Tax

**50%**  
Return on Equity


**Debt Free**

# Quarterly Financial Performance


Particulars <i>(INR Crore)</i>	Q1FY23	Q1FY22	YoY
Revenue	82.78	58.34	+41.9%
Gross Profit	34.52	16.8	+105.5%
<i>Gross Margin %</i>	<i>41.7%</i>	<i>28.8%</i>	<i>1,290 bps</i>
EBITDA	17.03	12.55	+35.6%
<i>EBITDA Margin %</i>	<i>20.6%</i>	<i>21.5%</i>	<i>(95) Bps</i>
Profit After Tax	14.15	10.71	+32.1%
<i>PAT Margin %</i>	<i>17.1%</i>	<i>18.4%</i>	<i>(127) Bps</i>
Earnings Per Share (INR)	14.15	10.71	+32.1%

Quarterly Financial Results for Quarter ending 30.6.22 are not strictly comparable with Quarter ending 30.6.21 due to the consolidation of Balaxi Healthcare LDA Angola (BHA) which became a wholly owned subsidiary of Balaxi Global DMCC with effect from 1st January 2022.


# Pharma Product Mix – Q1 FY23




### Geographies




### Products



### Dosage Forms




### Therapeutic Areas




# Historical Financial Performance

Particulars <i>(INR Crore)</i>	FY22	FY21	YoY
Revenue	279.39	231.33	+20.8%
Gross Profit	83.79	59.19	+41.6%
<i>Gross Margin %</i>	<b>30.0%</b>	<b>25.6%</b>	+440 bps
EBITDA	55.18	44.64	+23.6%
<i>EBITDA Margin %</i>	<b>19.7%</b>	<b>19.3%</b>	+45 bps
Profit After Tax	47.66	38.14	+25.0%
<i>PAT Margin %</i>	<b>17.1%</b>	<b>16.5%</b>	+60 bps
Earnings Per Share (INR)	47.66	38.14	+25.0%


# Pharma Product Mix – FY22




### Geographies




### Products




### Dosage Forms



### Therapeutic Areas



# Core Strategy: Enter, Expand & Excel



## Balaxi in 2020: Business Consolidation

- Presence across Angola, Guatemala and Dominican Republic
- Effective and efficient supply chain model consisting of 38 warehouses and a fleet of owned vehicles


## Balaxi in 2021-22: Expansion into New Geographies

- Aim to capture incremental market share in existing geographies by continuing to pursue various opportunities by leveraging physical assets
- Expanding presence in Honduras, El Salvador, Nicaragua, Zambia and Central African Republic
- Focus on offering a comprehensive product portfolio to fulfill consumer demand

## Balaxi in 2023 & Beyond

- Foray into other Latin American countries and CIS markets, replicating the established and differentiated business model
- Plans to enter new global markets backed by a EU GMP compliant manufacturing set up
- Focus on ideal mix of branded and generic medicines, maximizing returns in key geographies
- Targeting strong global presence in top 20 frontier markets over the next five years

## Our Offerings



# Balaxi

## Pharmaceuticals Limited



Plot No. 409, H.No. 8-2-293, 2nd Floor Maps Towers, Jubilee Hills, Road No:81,Hyderabad. Telangana

CIN: L25191TG1942PLC121598

### Company Investor Relations contact



Mr. Sunny Purohit



+91-40-2355-5300



[sunny@balaxi.com](mailto:sunny@balaxi.com)



[www.balaxipharma.in](http://www.balaxipharma.in)

NSE BALAXI

Bloomberg BALAXI:IN

# Thank You